Inhaled Pulmonary Surfactant Biomimetic Liposomes for Reversing Idiopathic Pulmonary Fibrosis through Synergistic Therapeutic Strategy

Inspired by the successful application of pulmonary surfactant (PS) replacement therapy in lung disease treatment, the authors developed PS nano-biomimetic liposomes to utilize its natural transport pathway for targeting AECs while reducing lung tissue clearance.